Aether Industries Q1 FY27: Contract-led growth, new capacity, and a platform bet on silicones

Aether Industries began FY27 with a strong quarter on both growth and profitability, as the company’s contract-led business models continued to gain share. In Q1 FY27, consolidated revenue from operations came in at INR 3,266 million, a 27% year-on-year increase versus INR 2,566 million in Q1 FY26. EBITDA rose 31% year on year to INR 1,028 million, with EBITDA margin at 31%. Profit after tax increased 33% year on year to INR 627 million, translating into a 19% PAT margin.

The quarter’s narrative was shaped by two themes. First, a mix shift toward higher-quality, contract-backed revenues via Contract Exclusive Manufacturing (CEM) and Contract Research and Manufacturing Services (CRAMS). Second, an expansion cycle that is bringing new assets online, while simultaneously widening the company’s R&D footprint and opening new strategic vectors such as advanced electronic materials and silicones technology development.

What changed in the revenue mix

Aether’s investor presentation highlighted that CEM and CRAMS together now contribute 60% of Q1 FY27 revenue, and management stated a clear line of sight to take this to 70% in the next couple of years.

On the mix for Q1 FY27, the deck disclosed the following shares by business model: 51.5% CEM, 39.1% Large Scale Manufacturing (LSM), 9.3% CRAMS, and 0.1% others. This matters because management emphasized that CEM carries EBITDA margins north of 28% to 30%, and therefore every incremental shift toward contract-led revenue improves the resilience of earnings.

The management commentary also reinforced that the contract-led models have moved from “promise to backbone,” with references to long-term arrangements and a deepening pipeline. The company said it onboarded 10 new customers during Q1 FY27 and cleared nine customer and certification audits, which is an operational precursor to incremental contracted revenue.

Financial snapshot

Note: The company also referenced an impact of INR 70 million loss of inventories on account of a fire at an external warehouse in March 2026 and certain year-end provisions.

Capacity and execution: Site 3++ ramp-up and Site 5 goes live

The quarter also carried several execution markers on the manufacturing side.

Site 3++ was commissioned in February 2026 and management stated it is ramping up as per expectations and contributing at healthy utilization. The management also indicated that this ramp-up has reached meaningful commercial contribution faster than earlier plans.

On capacity expansion, Site 5 was the key milestone. The presentation stated that Site 5 Phase One, comprising two production blocks, began commercial operation in Q1 FY27. Management added that Site 5, referred to as Magnum at Panoli, is planned as a larger 16-block site to be commissioned in phases, with Phase 1 now online. The deck further noted strong visibility for the first 10 production blocks.

Importantly, the company indicated that Phase 1 is expected to contribute revenue from Q2 FY27 onwards. Management also noted that several customers have already completed pre-audits for Site 5, and demand visibility is ahead of capacity.

For LSM, management stated that commercial sales of new LSM products from Site 5 began during the quarter, with revenue contribution expected from Q2 FY27. They described this as the first set of three new LSM products across pharmaceutical, agrochemicals, and material science, priced roughly in the USD 30 to 40 per kg range, while keeping product names confidential for competitive reasons.

R&D intensity and the next capability build

Aether continues to position R&D as the central engine behind CRAMS and CEM conversion. In Q1 FY27, the company spent INR 198.07 million on R&D, which was 6.16% of revenues for the quarter.

The deck highlighted interim capacity additions including the installation of 18 fume hoods. Management also stated that a new 400 MHz NMR is in service. Beyond the interim upgrades, a larger R&D facility is under development. Management described a future facility with around 15 new labs and close to 160 cumulative fume hoods, targeted for commissioning in FY2028. Separately, Site 1 (Catalyst) construction work is underway and is expected to complete by Q1 FY28.

The strategic intent is clear: more labs and larger R&D throughput enable the company to take on more complex chemistries, which supports both CRAMS work and the downstream conversion into longer-term CEM contracts.

New strategic vectors: advanced electronic materials and Dow-led silicones platform

While contract-led growth remains the central financial driver, management used the call to outline new platform opportunities.

Advanced electronic materials for 5G and AI hardware

Management described an initiative targeting advanced low dielectric materials used in high-speed printed circuit boards and copper-clad laminates inside 5G base stations and AI servers. The company framed its focus as upstream specialty monomers and coupling-agent related molecules that are low-volume, high-value, and difficult to manufacture.

On traction, management stated that manufacturing has already started on one stream at Site 3, qualification batches have been completed, samples submitted, and some smaller quantity orders are being delivered. They did not disclose customer names or order book details.

Exclusive research program with Dow for silicones

Aether also announced an exclusive multi-year collaborative research program with Dow Chemical to develop new manufacturing technologies for silicones. Management described this as a platform technology effort rather than a single product development. All research and pilot plant scale-up activities are to be carried out at Aether’s facilities in Surat.

Management indicated that investors should track progress in stages: process development, pilot-scale validation, and later the transition to a definitive commercial framework. They also stated that a future marker could be a capex commitment to a dedicated block or site for the silicones platform, while making it clear that they cannot put a revenue timeline at this stage.

Balance sheet priorities and near-term signposts

The CFO said working capital discipline remains a priority. While working capital intensity has improved overall, inventories remain elevated due to strategic raw material positioning and semi-finished inventory for Site 3++ and Site 5. The company expects a progressive decline in working capital days as revenues from Site 3++ materialize and Site 5 comes on stream.

Capex remains substantial. The company stated Q1 FY27 capex was INR 943 million, and guided FY27 capex at INR 3,000 million to INR 3,500 million, primarily for Site 5 and the new R&D site.

Takeaways

Aether’s Q1 FY27 performance reinforced that the business model shift toward contract-led revenue is already translating into strong growth and stable margins. The execution focus now shifts to converting capacity into cash flows, as Site 3++ ramps and Site 5 begins contributing from Q2 FY27.

At the same time, management is expanding the strategic perimeter through advanced electronic materials and a silicone platform technology partnership with Dow. These initiatives are early-stage and timelines for commercialization are not specified, but they add a longer runway to the company’s core CRAMS and CEM story if the execution milestones progress as described.